OcuTerra Therapeutics

Risk score

57
Large logo of OcuTerra Therapeutics

Headquarters

Flag of United States of AmericaUnited States of America

OcuTerra is in the process of developing an innovative eye drop, OTT166, specifically formulated to address diabetic eye disease. This pioneering treatment, which represents a significant advancement in the field, aims to effectively manage diabetic eye disease at an earlier stage, supported by established clinical evidence of its safety and biological effectiveness. OcuTerra is a forward-thinking ophthalmology company in the clinical stage, dedicated to creating groundbreaking medications for the treatment of ophthalmic conditions where the current standard of care of 'watch and wait' is inadequate in preventing or managing disease progression.